RedHill Biopharma (RDHL) Misses Q2 EPS by 4c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/4/2026
- Wall St slides after strong jobs report bolsters hawkish Fed bets
- US nonfarm payrolls blow past expectations in August; unemployment rate steady at 4.1%
- BofA's Hartnett says stay long commodities and gold as 'policy panic' works
- Oil slides on Friday, heads for weekly gain on US-Iran fight
- TikTok owner ByteDance said to secure $29.6bn loan for AI push
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
RedHill Biopharma Announces Q3/22 Results and Operational Highlights
November 29, 2022 8:00 AM ESTNon-binding agreement in principle reached with HCR on sale of Movantik to extinguish all debt obligations, to facilitate growth
Q3/22 Net revenues of $17.6 million; Operating loss of $7.1 million; Q3/22 positive cash flow from U.S. commercial operations, before interest payments[1]; Cash balance[2] of $31.4 million as of September 30, 2022
Talicia® and Movantik® have delivered year-to-date prescription growth of 65% and 6.7%, respectively; Q4/22 data to date indicate continued growth for both products
Discussions underway regarding opaganib for nuclear radiation injury with various government agencies with expedited Animal Rule pathway expected, and potential eligibility for a... More
